SCHEDULE: Royce & Associates Reports 7.81% Stake in Apyx Medical

Royce & Associates LP has disclosed a beneficial ownership of 7.81% of Apyx Medical Corporation's common stock as of June 30, 2026.

Summary

• Royce & Associates LP has filed a Schedule 13G, indicating it beneficially owns 3,274,064 shares of Apyx Medical Corporation's common stock.
• This represents 7.81% of the total class of securities outstanding.
• The filing is an amendment (Amendment No. 4) to a previous filing.
• Royce & Associates LP exercises sole voting power and sole dispositive power over these shares.
• The securities are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on an existing ownership stake rather than new company performance or strategic shifts.

Positives

• Significant institutional ownership reported by Royce & Associates LP, indicating confidence in the company.
• Royce & Associates LP holds sole voting and dispositive power, suggesting a clear investment strategy.
• The filing confirms that the shares were acquired and are held in the ordinary course of business.

Risks

• Potential for increased market activity or price volatility if Royce & Associates LP decides to adjust its holdings.
• Concentration of ownership by a single entity could influence corporate governance decisions.

Future Outlook

The filing does not contain forward-looking statements or guidance from the company. It solely reports on the ownership stake of Royce & Associates LP.

Management Comments

• Royce & Associates LP certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
• Royce & Associates LP certifies that, to the best of its knowledge and belief, the information set forth in this statement is true, complete and correct.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes. This filing indicates Royce & Associates LP's strategic interest in Apyx Medical Corporation within the broader medical technology sector.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership as a positive sign of investor confidence, potentially influencing share price.
• Management: May need to consider the influence of a significant shareholder in strategic decisions.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Royce & Associates LP will continue to hold its shares as reported, subject to its investment management agreements.
• Apyx Medical Corporation will continue its business operations as previously disclosed.

Key Dates

Keywords

Schedule 13G, Apyx Medical Corporation, Royce & Associates LP, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management